APO-Bortezomib bortezomib 3.5mg powder for injection vial

البلد: أستراليا

اللغة: الإنجليزية

المصدر: Department of Health (Therapeutic Goods Administration)

العنصر النشط:

bortezomib, Quantity: 3.5 mg

متاح من:

Arrotex Pharmaceuticals Pty Ltd

INN (الاسم الدولي):

Bortezomib

الشكل الصيدلاني:

Injection, powder for

تركيب:

Excipient Ingredients: mannitol

طريقة التعاطي:

Subcutaneous, Intravenous

الوحدات في الحزمة:

1

نوع الوصفة الطبية :

(S4) Prescription Only Medicine

الخصائص العلاجية:

Bortezomib, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.,Bortezomib, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.,Bortezomib is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy and who have progressive disease.

ملخص المنتج:

Visual Identification: White to off-white powder; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius

الوضع إذن:

Licence status A

تاريخ الترخيص:

2015-07-22